Evaluation of the Relationship Between miRNA-22-3p and Gal-9 Levels in Glioblastoma

OpenAlex English

BACKGROUND/AIM: Glioblastoma, the most prevalent primary malignant brain tumor, is significantly impacted by molecular mechanisms, including the function of microRNAs and galectins. The interplay between miRNA-22-3p and Galectin-9, a galactoside-binding lectin, is particularly notable. This study aimed to further investigate their roles in glioblastoma pathogenesis by analyzing the serum levels of these molecules in patients with glioblastoma. PATIENTS AND METHODS: This investigation included 50 subjects, consisting of 25 patients with glioblastoma and an equal number of healthy controls. Blood serum specimens were obtained for miRNA isolation and subsequent cDNA synthesis. The expression of the miRNA-22-3p gene was assessed using polymerase chain reaction (PCR), and a sandwich enzyme-linked immunosorbent assay (ELISA) was utilized to quantify serum Gal-9 concentrations. RESULTS: In patients diagnosed with glioblastoma, there was a significant elevation in miRNA-22-3p expression compared to healthy controls. However, despite a trend towards increased serum Gal-9 levels in the glioblastoma group, the difference did not reach statistical significance. CONCLUSION: Glioblastoma patients are characterized by increased Gal-9 serum levels and reduced miRNA-22-3p expression. These results indicate their potential as diagnostic and prognostic markers as well as therapeutic targets.